[8-K] Protalix BioTherapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Protalix BioTherapeutics, Inc. disclosed that it furnished a press release announcing its financial results for the fiscal quarter ended June 30, 2025 and provided a business and clinical update. The press release is furnished as Exhibit 99.1 to the Current Report on Form 8-K. The filing notes that the furnished information is not deemed "filed" under Section 18 of the Exchange Act and, therefore, is not incorporated by reference into registration statements or other filings unless specifically stated.

Positive

• Company disclosed that it furnished a press release containing financial results for the quarter ended June 30, 2025
• Business and clinical update was provided and made available as Exhibit 99.1, enabling stakeholders to locate the substantive disclosure

Negative

• None.

Insights

Securities Analyst

Routine disclosure; impact likely neutral pending the press release details.

The Form 8-K notifies the market that Protalix furnished a press release with quarter-end financial results and a business/clinical update, but includes no financial figures or operational detail. As written, the filing is procedural: it alerts stakeholders that substantive results exist in Exhibit 99.1. Materiality depends entirely on the contents of that press release; absent those figures here, investors cannot assess revenue, profitability, or clinical progress from this filing alone.

Corporate Governance Expert

Disclosure practice is standard; furnishing rather than filing limits legal exposure.

Protalix followed common practice by furnishing the press release as an exhibit and explicitly stating it is not "filed" under Section 18. That approach reduces incorporation risk for subsequent registration statements. The 8-K provides transparency that a company update exists, but offers no substantive content to evaluate governance, executive actions, or strategic change.

0001006281false00010062812025-08-142025-08-14

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 14, 2025

Protalix BioTherapeutics, Inc.

(Exact name of registrant as specified in its charter)

​

​	​	​	​	​
Delaware		001-33357		65-0643773
(State or other jurisdiction of incorporation)	​	(Commission File Number)	​	(IRS Employer Identification No.)
​	​	​	​	​
2 University Plaza	​	​	​	​
Suite 100	​	​	​	​
Hackensack, NJ	​	​	​	07601
(Address of principal executive offices)	​	​	​	(Zip Code)

​

 Registrant’s telephone number, including area code 201-696-9345

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐    Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, $0.001 par value	PLX	NYSE American

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

​

​

​

​

Item 2.02         Results of Operations and Financial Condition

On August 14, 2025, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025 and provided a business and clinical update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01         Financial Statements and Exhibits

Exhibit No.		Description
99.1	​	Press Release dated August 14, 2025
104	​	Cover Page Interactive Data File (embedded within the Inline XBRL document)
​	​	​

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 14, 2025	PROTALIX BIOTHERAPEUTICS, INC. ​ ​
	By:	/s/ Dror Bashan
		Name:	Dror Bashan
		Title:	President and Chief Executive Officer

​

​

FAQ

What did Protalix (PLX) disclose in this 8-K?

The company furnished a press release announcing its financial results for the quarter ended June 30, 2025 and provided a business and clinical update.

Where can I find the press release referenced by PLX?

The press release is furnished as Exhibit 99.1 to the Current Report on Form 8-K.

Is the press release in this 8-K considered "filed" under Section 18?

No. The filing explicitly states the information, including Exhibit 99.1, is not deemed to be "filed" under Section 18 of the Exchange Act.

Does the 8-K include financial figures or tables for Q2 2025?

No. This Form 8-K does not include any financial figures or tables; it only furnishes the press release as Exhibit 99.1.

Who signed the Form 8-K for Protalix?

The report is signed on behalf of the registrant by Dror Bashan, President and Chief Executive Officer.